XML 103 R83.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurements (Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Acquisition-related contingent consideration    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period $ 143,502 $ 46,005
Acquisitions 146,866 214,435
Amounts settled (55,896) (37,583)
Transfers (in) and/or out of Level 3 0 0
Measurement period adjustments 3,700 (13,434)
Changes in fair value recorded in earnings 23,823 (65,640)
Effect of currency translation 118 (281)
Fair Value Adjustments and Accretion 23,823 (65,640)
Payments and Other (55,778) (37,864)
End of period 262,113 143,502
Acquisition-related contingent consideration | Qualitest acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period 1,137 10,305
Fair Value Adjustments and Accretion (1,137) (4,168)
Payments and Other 0 (5,000)
End of period 0 1,137
Acquisition-related contingent consideration | Sumavel acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period 631 4,700
Fair Value Adjustments and Accretion (631) (4,069)
Payments and Other 0 0
End of period 0 631
Acquisition-related contingent consideration | Auxilium acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period 26,435 0
Fair Value Adjustments and Accretion 8,952 (62,370)
Payments and Other (14,290) (9,374)
End of period 21,097 26,435
Acquisition-related contingent consideration | Lehigh Valley Technologies, Inc. acquisitions    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period 97,003 0
Fair Value Adjustments and Accretion 30,676 31,071
Payments and Other (31,679) (22,268)
End of period 96,000 97,003
Acquisition-related contingent consideration | Voltaren Gel® acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period 0  
Fair Value Adjustments and Accretion (18,807)  
Payments and Other (8,853)  
End of period 118,395 0
Acquisition-related contingent consideration | Natesto™    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period 0 31,000
Fair Value Adjustments and Accretion   (26,687)
Payments and Other   0
End of period   0
Acquisition-related contingent consideration | Other    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning of period 18,296 0
Fair Value Adjustments and Accretion 4,770 583
Payments and Other (956) (1,222)
End of period 26,621 18,296
Acquisition-related contingent consideration and other measurement period adjustments    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions 150,566 201,001
Acquisition-related contingent consideration and other measurement period adjustments | Qualitest acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions 0 0
Acquisition-related contingent consideration and other measurement period adjustments | Sumavel acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions 0 0
Acquisition-related contingent consideration and other measurement period adjustments | Auxilium acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions 0 98,179
Acquisition-related contingent consideration and other measurement period adjustments | Lehigh Valley Technologies, Inc. acquisitions    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions 0 88,200
Acquisition-related contingent consideration and other measurement period adjustments | Voltaren Gel® acquisition    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions 146,055  
Acquisition-related contingent consideration and other measurement period adjustments | Natesto™    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions   (4,313)
Acquisition-related contingent consideration and other measurement period adjustments | Other    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisitions $ 4,511 $ 18,935